Candel Therapeutics Statistics
Share Statistics
Candel Therapeutics has 32.48M shares outstanding. The number of shares has increased by 10.94% in one year.
| Shares Outstanding | 32.48M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 7.83% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 20.08M |
| Failed to Deliver (FTD) Shares | 9.79K |
| FTD / Avg. Volume | 0.4% |
Short Selling Information
The latest short interest is 1.78M, so 5.48% of the outstanding shares have been sold short.
| Short Interest | 1.78M |
| Short % of Shares Out | 5.48% |
| Short % of Float | 8.9% |
| Short Ratio (days to cover) | 7.72 |
Valuation Ratios
The PE ratio is -1.12 and the forward PE ratio is -4.91.
| PE Ratio | -1.12 |
| Forward PE | -4.91 |
| PS Ratio | 0 |
| Forward PS | 50.8 |
| PB Ratio | 3.34 |
| P/FCF Ratio | -1.23 |
| PEG Ratio | n/a |
Enterprise Valuation
Candel Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 2.59, with a Debt / Equity ratio of 1.71.
| Current Ratio | 2.59 |
| Quick Ratio | 2.59 |
| Debt / Equity | 1.71 |
| Total Debt / Capitalization | 63.09 |
| Cash Flow / Debt | -1.57 |
| Interest Coverage | -74.69 |
Financial Efficiency
Return on equity (ROE) is -2.98% and return on capital (ROIC) is -108.12%.
| Return on Equity (ROE) | -2.98% |
| Return on Assets (ROA) | -0.92% |
| Return on Capital (ROIC) | -108.12% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -903.31K |
| Employee Count | 42 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 407.46% in the last 52 weeks. The beta is -0.87, so Candel Therapeutics 's price volatility has been lower than the market average.
| Beta | -0.87 |
| 52-Week Price Change | 407.46% |
| 50-Day Moving Average | 5.35 |
| 200-Day Moving Average | 5.92 |
| Relative Strength Index (RSI) | 81.23 |
| Average Volume (20 Days) | 2.45M |
Income Statement
In the last 12 months, Candel Therapeutics had revenue of $0 and earned -$37.94M in profits. Earnings per share was $-1.31.
| Revenue | 0 |
| Gross Profit | -23.98M |
| Operating Income | -38.39M |
| Net Income | -37.94M |
| EBITDA | -37.43M |
| EBIT | - |
| Earnings Per Share (EPS) | -1.31 |
Balance Sheet
The company has $35.41M in cash and $22.76M in debt, giving a net cash position of $12.65M.
| Cash & Cash Equivalents | 35.41M |
| Total Debt | 22.76M |
| Net Cash | 12.65M |
| Retained Earnings | -137.03M |
| Total Assets | 21.52M |
| Working Capital | 2.82M |
Cash Flow
In the last 12 months, operating cash flow was -$34.24M and capital expenditures -$457.00K, giving a free cash flow of -$34.70M.
| Operating Cash Flow | -34.24M |
| Capital Expenditures | -457.00K |
| Free Cash Flow | -34.70M |
| FCF Per Share | -1.2 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
CADL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -19.26% |
| FCF Yield | -15.71% |
Analyst Forecast
The average price target for CADL is $11, which is 61.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $11 |
| Price Target Difference | 61.8% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Scores
| Altman Z-Score | -13.8 |
| Piotroski F-Score | 3 |